Real-world treatment patterns across the pre-Bruton’s tyrosine kinase inhibitor(BTKi) and BTKi era and time to next treatment in patients with mantle cell lymphoma in Japan

ASH 2026 • MCL • Zanubrutinib • Poster

Koji Izutsu, MD PhD

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This retrospective real-world study used the Japanese Medical Data Vision database to describe changes in treatment patterns across the pre-Bruton’s tyrosine kinase inhibitors (BTKi) era (2012–2017) and BTKi era (2018–2025) from first-line to third-line, and to evaluate time to next treatment or inpatient death (TTNT) among patients with mantle cell lymphoma (MCL) in Japan. A total of 2,712 patients with newly diagnosed MCL were identified, including 1,908, 950, and 568 patients who initiated first-, second-, and third-line therapy, respectively. In first-line treatment, use of other chemoimmunotherapy regimens declined from 64.7% in the pre-BTKi era to 30.9% in the BTKi era, and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) from 26.7% to 9.6% across eras, while bendamustine-rituximab increased from 22.4% to 42.2% and ibrutinib-based therapy from 1.0% to 13.9% following BTKi introduction. In the second-line setting, other chemoimmunotherapy regimens use decreased from 55.1% to 40.0%, while bendamustine-rituximab decreased from 34.5% to 19.9%. Ibrutinib use increased substantially from 3.8% to 31.1%. Similar trends were observed in third-line. Stem cell transplantation use remained stable across eras and treatment lines (4%-8%). Median TTNT from first- to second-line therapy was longest with ibrutinib-based regimens (29.7 months; 95% CI, 23.2-40.7), followed by bendamustine-rituximab (24.0 months; 95% CI, 18.6-29.4) and stem cell transplant (14.3 months; 95% CI, 10.9-34.6). Similar patterns were observed in later treatment lines, with ibrutinib-based regimens consistently associated with the longest TTNT.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed